LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Search

Biogen Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

137.47 0.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

135.28

Max

137.65

Pagrindiniai rodikliai

By Trading Economics

Pajamos

394M

635M

Pardavimai

215M

2.6B

P/E

Sektoriaus vid.

13.46

35.69

Pelnas, tenkantis vienai akcijai

3.02

Pelno marža

23.995

Darbuotojai

7,605

EBITDA

457M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+21.72% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.9B

21B

Ankstesnė atidarymo kaina

137.43

Ankstesnė uždarymo kaina

137.47

Naujienos nuotaikos

By Acuity

50%

50%

131 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Biogen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-26 18:25; UTC

Pagrindinės rinkos jėgos

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

2025-09-28 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

2025-09-28 23:48; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-28 23:45; UTC

Rinkos pokalbiai

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

2025-09-28 23:34; UTC

Rinkos pokalbiai

Oil Falls on Likely Technical Correction -- Market Talk

2025-09-27 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-26 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

2025-09-26 20:54; UTC

Uždarbis

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

2025-09-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-26 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025-09-26 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-26 19:54; UTC

Rinkos pokalbiai

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

2025-09-26 19:53; UTC

Įsigijimai, susijungimai, perėmimai

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025-09-26 19:40; UTC

Uždarbis

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

2025-09-26 19:24; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

2025-09-26 19:17; UTC

Rinkos pokalbiai

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

2025-09-26 19:15; UTC

Rinkos pokalbiai

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

2025-09-26 19:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-26 19:03; UTC

Rinkos pokalbiai

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

2025-09-26 18:50; UTC

Rinkos pokalbiai
Uždarbis

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

2025-09-26 18:36; UTC

Rinkos pokalbiai

Silver Closes Out Week With Strong Surge -- Market Talk

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: Global Development Hasn't Received All Necessary Approvals >ING

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

2025-09-26 17:54; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

2025-09-26 16:56; UTC

Rinkos pokalbiai
Uždarbis

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

2025-09-26 16:41; UTC

Rinkos pokalbiai
Uždarbis

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

2025-09-26 16:26; UTC

Uždarbis

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

2025-09-26 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Biogen Inc Prognozė

Kainos tikslas

By TipRanks

21.72% į viršų

12 mėnesių prognozė

Vidutinis 167.2 USD  21.72%

Aukščiausias 224 USD

Žemiausias 118 USD

Remiantis 26 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Biogen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

26 ratings

12

Pirkti

14

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

118.15 / 121.17Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

131 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat